INTS · Intensity Therapeutics, Inc.
$4.43
+0.04 (+0.91%)
At close · Jul 23
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the cash and cash equivalents as of March 31, 2026, the Company's ability to continue its operations thereafter is dependent on obtaining additional capital, which is not within the Company's control. As a result, the Company believes there is substantial doubt about its ability to continue as a going concern.”View the 10-Q filed May 7, 2026
Market Cap
$11.97M
Shares
2.70M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$11.61M
+28.7%
FY2025
Diluted EPS
-$8.56
+70.7%
FY2025
Operating Cash Flow
-$9.23M
+39.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $5.79M | $6.79M | $10.5M | $4.79M | |
| $5.31M | $5.19M | $6.09M | $3.53M | |
| $11.1M | $11.97M | $16.59M | $8.32M | |
| -$11.1M | -$11.97M | -$16.59M | -$8.32M | |
| — | — | $0 | $305K | |
| $259K | $180K | $314K | $324K | |
| $152K | $186K | — | — | |
| — | $0 | $0 | $0 | |
| -$10.69M | -$11.61M | -$16.27M | -$10.54M | |
| USD/shares | — | -$8.56 | -$29.25 | -$34.50 |
| USD/shares | — | -$8.56 | -$29.25 | -$34.50 |
| shares | — | 1.36M | 556.28K | 344.65K |
| shares | — | 1.36M | 556.28K | 344.65K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.40×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.02×
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$11,972,000 | -$16,585,000 | -$8,319,000 |